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Julio Nunez, MD,* Luis Mainar, MD,* Jose V. Monmeneu, MD,† Oliver Husser, MD,*
Eloy Dominguez, MD,* Francisco J. Chorro, MD, FESC,* Angel Llacer, MD, FESC*
Valencia, Spain
Objectives We evaluated the prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging (CMR) in
patients with chest pain and known or suspected coronary artery disease.
Background Stress perfusion CMR has been incorporated in daily practice. Data on its prognostic value are preliminary.
Methods Dipyridamole stress CMR was performed in 420 patients with chest pain and known or suspected coronary ar-
tery disease. The extent (number of segments according to the 17-segment model) of abnormal wall motion at
rest (AWM-rest), abnormal wall motion with dipyridamole (AWM-D), perfusion deficit (at stress first-pass perfu-
sion imaging), and delayed enhancement (at late enhancement imaging) were analyzed.
Results During a median follow-up of 420 days, 41 major adverse cardiac events (MACE), including 9 cardiac deaths,
14 nonfatal myocardial infarctions, and 18 readmissions for unstable angina with documented abnormal an-
giography, were documented. The MACE were more frequent in patients with significant (1 segment) AWM-rest
(22% vs. 5%), AWM-D (21% vs. 4%), perfusion deficit (17% vs. 5%), and delayed enhancement (20% vs. 6%;
p 0.0001 in all cases). In a multivariate analysis adjusted for baseline characteristics, the extent of AWM-D
was independently related to MACE (hazard ratio [HR] 1.15 [95% confidence interval (CI) 1.06 to 1.24] per seg-
ment; p  0.0006) and to major events (cardiac death or nonfatal myocardial infarction; HR 1.15 [95% CI 1.05
to 1.26] per segment; p  0.002).
Conclusions Dipyridamole stress CMR is useful for predicting the outcome of patients with known or suspected coronary
artery disease. (J Am Coll Cardiol 2007;50:1174–9) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.016o
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hn patients with known or suspected myocardial ischemia,
oninvasive techniques are necessary not only to establish or
xclude the presence of coronary artery disease but also to
efine management and prognosis (1,2). Cardiovascular
agnetic resonance imaging (CMR) is becoming an inte-
ral part of the diagnostic workup of patients with ischemic
eart disease (1).
So far, the usefulness of vasodilator stress CMR for
redicting clinical events has not been proven. The purpose
f the present study was to determine the prognostic value
rom the *Cardiology Department, University Clinic Hospital, University of Valen-
ia, Valencia, Spain; and †Exploraciones Radiolo´gicas Especiales Sociedad Ano´nima,
alencia, Spain. This work was supported by the grant Bayer 2007 from the Spanish
ociety of Cardiology.o
Manuscript received February 27, 2007; revised manuscript received June 5, 2007,
ccepted June 19, 2007.f dipyridamole stress CMR in patients with known or
uspected ischemic heart disease.
ethods
tudy group. The study population was represented by
20 consecutive patients with chest pain of possible
oronary origin who underwent dipyridamole stress
MR between January 2003 and January 2006 owing to
nconclusive exercise testing (18%), altered electrocardio-
ram (22%), inability to exercise (23%), evaluation of the
everity of intermediate lesions (10%), and first choice
27%).
Exclusion criteria were a history of myocardial infarction
r coronary revascularization within the last 3 months,
emodynamic instability, asthma, and a follow-up duration
f 6 months.
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September 18, 2007:1174–9 Prognostic Value of Dipyridamole Stress CMRAll data were prospectively recorded. The study protocol
as approved by an ethics committee, and all subjects gave
nformed consent.
MR study. All patients were examined with a 1.5-T
ystem (Sonata Magnetom, Siemens, Erlangen, Germany).
ll images were acquired by a phased-array body surface coil
uring breath holds and were electrocardiogram triggered.
INE IMAGES AT REST. Left ventricular function was as-
essed using cine images in 2-, 3-, 4-chamber, and short-
xis views using a true fast imaging with steady-state
recession sequence (TrueFISP) (repetition time/echo time
.8 ms/1.2 ms, flip angle 58°, matrix 256  256, field of
iew 320  270 mm, slice thickness 6 mm).
IRST-PASS PERFUSION IMAGING. Vasodilatation was in-
uced with dipyridamole (0.84 mg/kg body weight) delivered
ntravenously over 6 min. Two minutes after the end of
ipyridamole infusion, 0.1 mmol/kg gadopentate dimeglumine
Magnograf, Schering, Berlin, Germany) was injected intrave-
ously at a speed of 5 ml/s. Then 4 sections equally
eparated in the short-axis view and 2 in the 2- and
-chamber long-axis views were acquired for first-pass
erfusion imaging (TrueFISP with a notched saturation
ulse, inversion time 125 ms, repetition time/echo time
02 ms/1 ms, flip angle 50°, matrix 192  96, field of
iew 350  220 mm, slice thickness 8 mm).
INE IMAGES AT STRESS. Once the peak myocardial en-
ancement was reached, to assess left ventricular function
ithin the peak dipyridamole-induced vasodilatation
approximately 3 min after infusion) we used a fast-
cquisition multislice TrueFISP cine image sequence
repetition time/echo time 35 ms/1.1 ms, flip angle 65°,
atrix 192  159, field of view 350  304 mm, slice
hickness 8 mm) acquiring over a 14-s period 4 slices in
he short-axis view in the same locations evaluated for
ine images at rest.
ATE ENHANCEMENT IMAGING. Late enhancement imag-
ng was performed 10 min after contrast injection in the
ame locations evaluated for cine images at rest (segmented
nversion recovery TrueFISP, repetition time/echo time 700
s/1.26 ms, flip angle 45°, matrix 256  184, field of view
40  235 mm, slice thickness 8 mm). The inversion time
as adjusted to null normal myocardium.
MR data analysis. Cardiovascular magnetic resonance
tudies were analyzed by an experienced observer blinded to
ll patient data and using customized software (Syngo,
iemens). The 17-segment model was applied (3). We
valuated 4 dipyridamole stress CMR-derived indexes (Fig.
, Online Video 1):
. Wall motion at rest (AWM-rest): number of seg-
ments showing hypokinesis, akinesis, or dyskinesis at
baseline.. Wall motion with dipyri-
damole (AWM-D): number
of segments showing hypoki-
nesis, akinesis, or dyskinesis
at stress.
. Perfusion deficit with dipyr-
idamole: number of segments
showing persistent delay (in
at least 3 consecutive tempo-
ral images) in the visual anal-
ysis of enhancement pattern
during the first pass of con-
trast through the myocar-
dium (4).
. Delayed enhancement: num-
ber of segments showing en-
hancement in late enhance-
ment imaging.
he AWM, AWM-D, perfusion deficit, and delayed en-
ancement were categorized according to the best cut-off
alue in receiver-operating characteristic curves (0 to 1
egment vs. 1 segment in all cases) to predict major
dverse cardiac events (MACE) during follow-up. In our
aboratory, interobserver agreement concerning these 4
MR indexes is 90%.
Abbreviations
and Acronyms
AWM-D  extent (number
of segments) of abnormal
wall motion with
dipyridamole
AWM-rest  extent
(number of segments) of
abnormal wall motion at
rest
CMR  cardiovascular
magnetic resonance
imaging
MACE  major adverse
cardiac events
TrueFISP  true fast
imaging with steady-state
precession sequence
Figure 1 Dipyridamole Stress CMR Allows Assessment of AWM-
rest and -D, Perfusion Deficit, and Delayed Enhancement
Example of a patient with stress-induced systolic dysfunction and perfusion
deficit in the inferior area (arrows) and a small area of delayed enhancement
in the anterior territory (bottom right panel, arrow). AWM-D  abnormal wall
motion with dipyridamole; AWM-rest  abnormal wall motion at rest; CMR 
cardiovascular magnetic resonance imaging.
Please see the Appendix for accompanying video.
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Prognostic Value of Dipyridamole Stress CMR September 18, 2007:1174–9ardiac catheterization. A CMR study-related cardiac
atheterization (within the subsequent 3 months) was car-
ied out in 145 patients. A CMR study-related revascular-
zation was performed in 80 patients: percutaneous coronary
ntervention in 65 and coronary artery bypass grafting in 15
Table 1).
nd points and follow-up. The primary end point was
ACE and included cardiac death, nonfatal myocardial
nfarction, and admission for unstable angina (whichever
ccurred first). All MACE were reviewed, and consensus
etween 2 cardiologists was required to finally designate a
ACE. Admission for unstable angina required the pres-
nce of chest pain with unstable characteristics leading to
ospital admission and evidence of abnormal coronary
ngiography.
Baseline Characteristics of the Whole StudyGroup and of Pa i nts With and ithout MACE
Table 1 Baseline Characteristics of the WhoGroup and of Patients With and Wit
Study Grou
Patients (n) 420
Age (yrs) 64  11
Male gender (%) 255 (61)
Diabetes (%) 110 (26)
Hypertension (%) 211 (50)
Hypercholesterolemia (%) 186 (44)
Current smoker (%) 63 (15)
Previous PCI (%) 60 (14)
Previous CABG (%) 35 (8)
Previous revascularization (%) 90 (21)
Previous infarction (%) 95 (23)
ST-segment depression (%) 48 (11)
T-wave inversion (%) 54 (13)
Left bundle branch block (%) 15 (4)
Treatment with beta-blockers (%) 168 (40)
Treatment with nitrates (%) 147 (35)
Treatment with statins (%) 176 (42)
Related cardiac catheterization (%) 145 (34)
Related PCI (%) 65 (15)
Related CABG (%) 15 (4)
Related revascularization (%) 80 (19)
CABG  coronary artery bypass graft; MACE  major adverse cardiac
Cardiovascular Magnetic Resonance Imaging Daof the Whole Study Group and of Patients With
Table 2 Cardiovascular Magnetic Resonancof the Whole Study Group and of Pa
Study Group
Patients (n) 420
Ejection fraction (%) 61 12
End-diastolic volume (ml/m2) 67 21
End-systolic volume (ml/m2) 28 20
Left ventricular mass (g/m2) 77 20
AWM-rest (segments) 1.4 2.8
AWM-D (segments) 1.9 3.2
Perfusion deficit (segments) 2.7 3.7
Delayed enhancement (segments) 1.2 2.3AWM-D number of segments with abnormal wall motion with dipyridamole;
MACE  major adverse cardiac events.The secondary end point was major events (cardiac
eath or nonfatal myocardial infarction, whichever oc-
urred first).
tatistical analysis. Continuous data were expressed as the
ean  standard deviation and were compared by the
npaired t test. Proportions were compared by the chi-
quare statistic; the Fisher exact test was used when appro-
riate. Survival distributions for the time to event were
stimated using the Kaplan-Meier method and the log rank
est.
The association of variables with MACE and major
vents was assessed with the Cox proportional hazard
egression model using stepwise multivariate procedures.
ariables with a p value of0.1 in the univariate analysis in
ables 1 to 4 were tested in multivariate procedures. A
udy
MACE
MACE No MACE p Value
41 379
68  10 64  11 0.03
28 (68) 227 (60) 0.3
19 (46) 91 (24) 0.004
32 (78) 179 (47) 0.001
26 (63) 160 (42) 0.01
6 (15) 57 (15) 0.9
7 (17) 53 (14) 0.6
11 (27) 24 (6) 0.001
16 (39) 74 (19) 0.008
23 (56) 72 (19) 0.001
5 (12) 43 (11) 0.8
5 (12) 49 (13) 0.9
2 (5) 13 (3) 0.9
16 (39) 152 (40) 0.9
18 (44) 129 (34) 0.6
16 (39) 160 (42) 0.5
18 (44) 127 (33) 0.2
7 (17) 58 (15) 0.8
2 (5) 13 (3) 0.6
9 (22) 71 (19) 0.7
; PCI  percutaneous coronary intervention.
ithout MACE
ging Data
s With and Without MACE
MACE No MACE p Value
41 379
55 14 62 11 0.009
72 25 66 21 0.2
34 20 27 19 0.03
80 23 75 24 0.2
3.4 3.4 1.2 2.6 0.001
4.6 4.1 1.6 2.9 0.001
4.7 3.9 2.5 3.6 0.001
3 3.3 1 2.1 0.001le St
hout
ptand W
e Ima
tientAWM-rest number of segments with abnormal wall motion at rest;
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September 18, 2007:1174–9 Prognostic Value of Dipyridamole Stress CMRignificance of 0.05 was required for a variable to be
ncluded in the final multivariate model. Hazard ratios with
he corresponding 95% confidence intervals were estimated.
he predictive ability of the Cox models was assessed by
stimating the Harrell C-statistics before and after the
ddition of CMR data.
Statistical significance was considered to be p  0.05.
he SPSS 11.0 (SPSS, Chicago, Illinois) and STATA 9.0
StataCorp, College Station, Texas) computer programs
ere used throughout.
esults
ll patients were followed up for at least 6 months (495 
09 days, range 184 to 1,372 days, median 420 days); 41
ACE including 23 major events (9 cardiac deaths and 14
onfatal myocardial infarctions) and 18 readmissions for
nstable angina were detected. The baseline characteristics
re shown in Tables 1 and 2.
ACE. Patients with MACE had a worse clinical profile
Table 1). In the univariate analysis, all dipyridamole stress
MR indexes evaluated were related to MACE (Table 2,
igs. 2 and 3).
In the multivariate analysis, the extent of AWM-D was
he only dipyridamole stress CMR index independently
elated to MACE (Table 5).
The C-statistic of the model with baseline characteristics
ncluded in Table 1 (0.795) was improved by the addition of
MR data included in Table 2 (0.812).
ajor events. Patients with major events had a worse
aseline Characteristics of Patients With andithout Major Ev nts in the Whole Study Group
Table 3 Baseline Characteristics of Patients With andWithout Major Events in the Whole Study Group
Major
Events
No Major
Events p Value
Patients (n) 23 397
Age (yrs) 70  6 64  11 0.001
Male gender (%) 15 (65) 240 (60) 0.8
Diabetes (%) 13 (56) 97 (24) 0.002
Hypertension (%) 21 (91) 190 (48) 0.001
Hypercholesterolemia (%) 14 (61) 172 (43) 0.1
Current smoker (%) 2 (9) 61 (15) 0.5
Previous PCI (%) 3 (13) 57 (14) 0.9
Previous CABG (%) 6 (26) 29 (7) 0.008
Previous revascularization (%) 7 (30) 83 (21) 0.3
Previous infarction (%) 11 (48) 84 (21) 0.008
ST-segment depression (%) 3 (13) 45 (11) 0.7
T-wave inversion (%) 2 (9) 52 (13) 0.7
Left bundle branch block (%) 1 (4) 14 (3) 0.6
Treatment with beta-blockers (%) 11 (48) 157 (39) 0.7
Treatment with nitrates (%) 6 (26) 141 (35) 0.6
Treatment with statins (%) 10 (43) 166 (42) 0.9
Related cardiac catheterization (%) 7 (30) 138 (35) 0.8
Related PCI (%) 3 (13) 62 (16) 0.9
Related CABG (%) 1 (4) 14 (3) 0.6
Related revascularization (%) 4 (17) 76 (19) 0.9
bbreviations as in Table 1.linical profile (Table 3) and a larger extent of AWM-rest, AWM-D, perfusion deficit, and delayed enhancement
Table 4, Fig. 2).
In the multivariate analysis, the extent of AWM-D was
he only dipyridamole stress CMR index independently
elated to major events (Table 5).
The C-statistic of the model with baseline characteristics
ncluded in Table 3 (0.779) was improved by the addition of
MR data included in Table 4 (0.836).
onrevascularized patients. In the 340 nonrevascularized
atients, we detected 32 MACE, including 8 cardiac deaths,
1 nonfatal myocardial infarctions, and 13 readmissions for
nstable angina.
Similarly to the whole group, the extent of AWM-D was
he only dipyridamole stress CMR index independently
elated to MACE and major events (Fig. 3, Table 5).
ombination of CMR indexes. We created a 5-step score
from 0 to 4 indexes) according to the number of abnormal
MR indexes detected. The percentage of MACE (2%,
0%, 17%, 16%, and 24%; p  0.0001 for the trend) and of
ajor events (2%, 6%, 9%, 8%, and 11%; p  0.06 for the
rend) increased with the number of abnormal CMR
ndexes detected. In the multivariate analysis this score was
ot selected as an independent variable.
iscussion
he main finding of the present study is that dipyridamole
tress CMR provides independent information for predict-
ng cardiac events in patients with chest pain and known or
uspected ischemic heart disease.
tress CMR and prognosis of coronary artery dis-
ase. Stress CMR is likely to be useful for establishing the
rognosis in patients with chest pain and known or sus-
ected ischemic heart disease. However, so far, only dobu-
amine stress CMR (5,6) has been proven to be useful. Data
oncerning the prognostic value of vasodilator stress CMR
re scarce (7). The present study is the first to assess the
sefulness of vasodilator stress CMR for predicting spon-
aneous clinical events.
Cardiovascular magnetic resonance imaging allows a com-
rehensive evaluation of coronary patients (8). In fact, all 4
ardiovascular Magnetic Resonance Imaging Dataf Patients With nd Without M jor Events in thehole Study Group
Table 4
Cardiovascular Magnetic Resonance Imaging Data
of Patients With and Without Major Events in the
Whole Study Group
Major
Events
No Major
Events p Value
Patients (n) 23 397
Ejection fraction (%) 56 17 61 11 0.1
End-diastolic volume (ml/m2) 77 26 66 20 0.08
End-systolic volume (ml/m2) 37 23 27 19 0.06
Left ventricular mass (g/m2) 83 24 75 25 0.2
AWM-rest (segments) 3.2 3.8 1.3 2.7 0.02
AWM-D (segments) 4.3 4.3 1.8 3.1 0.01
Perfusion deficit (segments) 5 4.4 2.6 3.6 0.02
Delayed enhancement (segments) 2.4 3 1.1 2.2 0.05bbreviations as in Table 2.
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Prognostic Value of Dipyridamole Stress CMR September 18, 2007:1174–9MR indexes assessed—AWM-rest, AWM-D, perfusion
eficit, and delayed enhancement—related to prognosis.
all motion at stress. Only AWM-D afforded indepen-
ent information: each additional dysfunctional segment
ncreased the risk of events by 15%.
Abnormal wall motion at peak stress integrates the
nformation provided by systolic function at rest plus stress-
nduced systolic function. This observation is in accordance
ith studies using nuclear imaging techniques (2), stress
chocardiography (9), and dobutamine CMR (5,6), sug-
Figure 2 MACE and Major Events Depending on the Presence o
of Abnormal (>1 Segment) Stress Dipyridamole CMR
AWM-D  number of segments with abnormal wall motion with dipyridamole; AWM
segments with abnormal wall motion at rest; CMR  cardiovascular magnetic reso
Figure 3 Kaplan-Meier Survival Distributions Without MACE Ba
the Presence or Absence of Abnormal Wall Motion Wi
(Top) Unadjusted curves; (bottom) survival curves adjusted for diabetes, hyperten
Dashed lines  presence (1 segment) of abnormal wall motion with dipyridamol
AWM-D  number of segments with abnormal wall motion with dipyridamole; MACesting that wall motion at peak stress is the most signifi-
ant predictor of cardiac events.
erfusion imaging. Quantitative assessment of perfusion is
ossible but it is time consuming. Moreover, TrueFISP
equences with high dose of contrast offer high image
uality, but occasionally transitory artifacts make quantita-
ive assessment difficult. The accuracy of visual analysis, as
e did, has been encouraging (1,4).
The prognostic value of perfusion deficit was weaker than
hat of AWM-D. Revascularization guided by perfusion
sence
es in the Whole Group
number of
imaging; MACE  major adverse cardiac events.
n
pyridamole
nd previous infarction; (left) whole group; (right) nonrevascularized patients.
lines  absence (0 to 1 segment) of abnormal wall motion with dipyridamole.
ajor adverse cardiac events.r Ab
Index
-rest 
nancesed o
th Di
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e; solid
E  m
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September 18, 2007:1174–9 Prognostic Value of Dipyridamole Stress CMReficit might partially attenuate the deleterious effect of this
nding. However, results were identical after censoring those
0 patients who underwent a CMR study-related revascular-
zation procedure. This reinforces the value of wall motion at
tress in relation to the spontaneous evolution of patients.
ate enhancement imaging. The role of delayed enhance-
ent for the assessment of myocardial viability (8,10,11)
nd the definition of patient outcome (12) is in expansion.
owever our results suggest that in patients evaluated for
hest pain the prediction of clinical events can be improved
y the simultaneous assessment of other indexes, especially
he extent of systolic dysfunction at stress.
onclusions
n patients with chest pain and known or suspected isch-
mic heart disease, dipyridamole stress CMR predicts clin-
cal events over the subsequent months. The extent of
bnormal wall motion at stress is the CMR index most
losely related to outcome.
eprint requests and correspondence: Dr. Vicente Bodi, Cardi-
logy Department, University Clinic Hospital, Blasco Ibanez 17,
6010 Valencia, Spain. E-mail: vicentbodi@hotmail.com.
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APPENDIX
or an accompanying video to Figure 1,
atients
jor Events
scularized Patients
Nonrevascularized Patients
p Value HR (95% CI) p Value
0.05 2.2 (1.1–4.8) 0.03
0.02 3.1 (1.2–7.8) 0.01
0.0005 3.6 (1.6–8) 0.002
0.0006 1.4 (1.2–1.7) 0.0001
0.05 2.8 (1.1–7.4) 0.03
0.01 5.1 (1.1–23.1) 0.03
0.002 1.17 (1.06–1.29) 0.002
; CI  confidence interval; HR  hazard ratio; MACE major adversentszed P
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uplease see the online version of this article.
